FIELD: medicine; pharmaceutics.
SUBSTANCE: object 1 is the use of 5-aminolevulinic acid or its salt or composite ester for enhancing an antitumor effect of an immune checkpoint inhibitor, where the immune checkpoint inhibitor is an anti-PD-L1 antibody or an anti-PD-1 antibody, and where the specified 5-aminolevulinic acid or its salt or composite ester is systematically injected to a subject who needs it. Object 2 is the use of 5-aminolevylinic acid or its salt or composite ester, when producing a drug for enhancing an antitumor effect of the anti-PD-L1 antibody or the anti-PD-1 antibody.
EFFECT: enhancing an antitumor effect of immune checkpoint inhibitors, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, with 5-aminolevulinic acid.
4 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER AGENT | 2016 |
|
RU2729936C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER | 2018 |
|
RU2783759C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| CANCER CHEMOTHERAPY USING AZABICYCLO COMPOUND | 2018 |
|
RU2821034C2 |
| ANTICANCER THERAPY USING COMPOUNDS OF 3,5-DISUBSTITUTED BENZENE ALKYNYL AND PEMBROLIZUMAB | 2020 |
|
RU2822064C2 |
| COMBINED TREATMENT OF MALIGNANT NEOPLASM USING SULPHONAMIDE COMPOUND AND IMMUNOREGULATOR | 2020 |
|
RU2820817C2 |
